Health Condition 1: O- Medical and Surgical Health Condition 2: 8- Other Procedures
Conditions
Interventions
Intervention1: 2mg of Intrathecal Nalbuphine as an adjuvant to Ropivacaine: Group A will receive 2mg of Nalbuphine made up to 0.5ml volume with normal saline +isobaric Ropivacaine 0.75% 3ml (Total vol
Sponsors
Veer Surendra Sai institute of medical science and research
Eligibility
Inclusion criteria
Inclusion criteria: ASA grade 1&2 Planned for elective lower limb surgeries
Exclusion criteria
Exclusion criteria: Pregnant patients Patients with co morbidities like hypertension and diabetes Patient having contraindications to SAB Weight more than 100kg and less than 30kg Patients receiving CNS depressant drugs Patient having cardiac renal respiratory disease H/o adverse reactions to Ropivacaine and Nalbuphine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intrathecal Nalbuphine can be used as a good adjuvant to subarachnoid block as it can prolong both sensory and motor blockade with minimal side effects Low dose Nalbuphine (2mg) will be producing equal motor and prolonged analgesia as compared to 5mg of Nalbuphine with lesser side effectsTimepoint: 4-6hours | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse effectsTimepoint: Within 10 hour after spinal anaesthesia | — |
Countries
India
Contacts
Public ContactDr Dulal Kisun Soren
Department of Anaesthesiology and critical care,VSSIMSAR,BURLA
Outcome results
None listed